Pfizer, Inc. (NYSE:PFE) updated its FY17 earnings guidance on Tuesday. The company provided EPS guidance of $2.54-2.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.55. The company issued revenue guidance of $52-54 billion, compared to the consensus revenue estimate of $52.78 billion.
Several equities analysts have recently weighed in on the company. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the company a neutral rating in a research report on Wednesday, August 2nd. Morgan Stanley restated a neutral rating and issued a $35.00 target price (down previously from $38.00) on shares of Pfizer in a research report on Monday, June 12th. Berenberg Bank set a $39.00 target price on Pfizer and gave the company a neutral rating in a research report on Tuesday, August 1st. Citigroup Inc. downgraded Pfizer from a neutral rating to a sell rating and reduced their price objective for the stock from $38.00 to $31.00 in a research report on Tuesday, May 16th. Finally, BMO Capital Markets reiterated a hold rating and set a $33.00 price objective on shares of Pfizer in a research report on Thursday, April 27th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the stock. Pfizer has an average rating of Hold and an average target price of $37.77.
Shares of Pfizer, Inc. (PFE) traded down 0.51% during midday trading on Friday, hitting $33.25. The stock had a trading volume of 12,928,473 shares. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.38. The stock has a 50-day moving average price of $33.40 and a 200-day moving average price of $33.31. The stock has a market cap of $198.43 billion, a P/E ratio of 24.32 and a beta of 1.00.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The business had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the company posted $0.64 earnings per share. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.85%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
In other news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Pfizer, Inc. (NYSE:PFE) Releases FY17 Earnings Guidance” was first published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/14/pfizer-inc-nysepfe-issues-fy17-earnings-guidance-updated.html.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sage Capital Advisors llc bought a new position in Pfizer during the second quarter worth approximately $2,342,000. Hudock Capital Group LLC raised its position in Pfizer by 3.1% in the second quarter. Hudock Capital Group LLC now owns 78,762 shares of the biopharmaceutical company’s stock worth $2,645,000 after buying an additional 2,392 shares in the last quarter. Buckingham Asset Management LLC raised its position in Pfizer by 45.8% in the second quarter. Buckingham Asset Management LLC now owns 73,341 shares of the biopharmaceutical company’s stock worth $2,464,000 after buying an additional 23,054 shares in the last quarter. Pacer Advisors Inc. raised its position in Pfizer by 19.5% in the second quarter. Pacer Advisors Inc. now owns 193,306 shares of the biopharmaceutical company’s stock worth $6,493,000 after buying an additional 31,511 shares in the last quarter. Finally, Windsor Capital Management LLC raised its position in Pfizer by 12.9% in the second quarter. Windsor Capital Management LLC now owns 14,183 shares of the biopharmaceutical company’s stock worth $476,000 after buying an additional 1,619 shares in the last quarter. Institutional investors and hedge funds own 70.10% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.